Carsten Boess
Director/Board Member bei ROCKET PHARMACEUTICALS, INC.
Vermögen: - $ am 31.03.2024
Profil
Carsten Boess was the founder of Kiniksa Pharmaceuticals Ltd.
(founded in 2015) where he held the title of Executive Vice President-Corporate Affairs from 2015 to 2020.
He currently holds the position of Independent Director at Avidity Biosciences, Inc., Non-Executive Director at Achilles Therapeutics UK Ltd., Independent Director at Rocket Pharmaceuticals, Inc., and Independent Non-Executive Director at Achilles Therapeutics Plc.
Mr. Boess has also held former positions including Senior Director-Finance & Information Technology at Novozymes A, Independent Director at Inotek Pharmaceuticals Corp., Independent Director at Health Sciences Acquisitions Corp.
2, Chief Financial Officer at Alexion Pharmaceuticals, Inc. from 2004 to 2005, Vice President-Finance & International Operations at Novo Nordisk A from 1991 to 2004, Vice President-International Operations at Insulet Corp.
from 2006 to 2011, Executive Vice President-Finance at EMD Serono, Inc. from 2005 to 2006, Manager-Investor Relations & Finance at Novo Nordisk North America, Inc., and Chief Financial Officer & Senior Vice President at Synageva BioPharma Corp.
from 2011 to 2015.
Mr. Boess obtained undergraduate and graduate degrees from the University of Southern Denmark.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 | |
AVIDITY BIOSCIENCES INC
-.--% | 15.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
| 01.02.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Carsten Boess
| Unternehmen | Position | Beginn |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Director/Board Member | 01.01.2016 |
| AVIDITY BIOSCIENCES, INC. | Director/Board Member | 13.04.2020 |
| ACHILLES THERAPEUTICS PLC | Director/Board Member | 01.04.2020 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 01.04.2020 |
Ehemalige bekannte Positionen von Carsten Boess
| Unternehmen | Position | Ende |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Founder | 01.02.2020 |
| SYNAGEVA BIOPHARMA CORP | Director of Finance/CFO | 01.01.2015 |
| INSULET CORPORATION | Director of Finance/CFO | 05.03.2009 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 01.05.2006 |
| ALEXION PHARMACEUTICALS, INC. | Director of Finance/CFO | 01.01.2005 |
Ausbildung von Carsten Boess
| University of Southern Denmark | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| INSULET CORPORATION | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
| Novo Nordisk North America, Inc. | |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Health Sciences Acquisitions Corp. 2
 Health Sciences Acquisitions Corp. 2 Financial ConglomeratesFinance Health Sciences Acquisitions Corp. 2 is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on May 25, 2020 and is headquartered in New York, NY. | Finance |
